The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Psychedelic Drugs Market Research Report 2025
Synopsis
The global Psychedelic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Psychedelic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psychedelic Drugs.
Report Scope
The Psychedelic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Psychedelic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Psychedelic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
COMPASS Pathways PLC
Pfizer
Eli Lilly
GlaxoSmithKline
Cybin Inc
Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Jannsen
Acadia Pharmaceuticals
Intellipharmaceutics
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical
Segment by Type
Psilocybin
LSD
MDMA
DMT
Ketamine
Others
Segment by Application
Depressive Disorders
Post-Traumatic Stress Disorders
Substance Abuse Disorders
Obsessive Compulsive Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Psychedelic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Psychedelic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Psychedelic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psychedelic Drugs.
Report Scope
The Psychedelic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Psychedelic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Psychedelic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
COMPASS Pathways PLC
Pfizer
Eli Lilly
GlaxoSmithKline
Cybin Inc
Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Jannsen
Acadia Pharmaceuticals
Intellipharmaceutics
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical
Segment by Type
Psilocybin
LSD
MDMA
DMT
Ketamine
Others
Segment by Application
Depressive Disorders
Post-Traumatic Stress Disorders
Substance Abuse Disorders
Obsessive Compulsive Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Psychedelic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Psychedelic Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Psilocybin
1.2.3 LSD
1.2.4 MDMA
1.2.5 DMT
1.2.6 Ketamine
1.2.7 Others
1.3 Market by Application
1.3.1 Global Psychedelic Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Depressive Disorders
1.3.3 Post-Traumatic Stress Disorders
1.3.4 Substance Abuse Disorders
1.3.5 Obsessive Compulsive Disorders
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Psychedelic Drugs Market Perspective (2019-2030)
2.2 Psychedelic Drugs Growth Trends by Region
2.2.1 Global Psychedelic Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Psychedelic Drugs Historic Market Size by Region (2019-2024)
2.2.3 Psychedelic Drugs Forecasted Market Size by Region (2025-2030)
2.3 Psychedelic Drugs Market Dynamics
2.3.1 Psychedelic Drugs Industry Trends
2.3.2 Psychedelic Drugs Market Drivers
2.3.3 Psychedelic Drugs Market Challenges
2.3.4 Psychedelic Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Psychedelic Drugs Players by Revenue
3.1.1 Global Top Psychedelic Drugs Players by Revenue (2019-2024)
3.1.2 Global Psychedelic Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Psychedelic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Psychedelic Drugs Revenue
3.4 Global Psychedelic Drugs Market Concentration Ratio
3.4.1 Global Psychedelic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Psychedelic Drugs Revenue in 2023
3.5 Psychedelic Drugs Key Players Head office and Area Served
3.6 Key Players Psychedelic Drugs Product Solution and Service
3.7 Date of Enter into Psychedelic Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Psychedelic Drugs Breakdown Data by Type
4.1 Global Psychedelic Drugs Historic Market Size by Type (2019-2024)
4.2 Global Psychedelic Drugs Forecasted Market Size by Type (2025-2030)
5 Psychedelic Drugs Breakdown Data by Application
5.1 Global Psychedelic Drugs Historic Market Size by Application (2019-2024)
5.2 Global Psychedelic Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Psychedelic Drugs Market Size (2019-2030)
6.2 North America Psychedelic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Psychedelic Drugs Market Size by Country (2019-2024)
6.4 North America Psychedelic Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Psychedelic Drugs Market Size (2019-2030)
7.2 Europe Psychedelic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Psychedelic Drugs Market Size by Country (2019-2024)
7.4 Europe Psychedelic Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Psychedelic Drugs Market Size (2019-2030)
8.2 Asia-Pacific Psychedelic Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Psychedelic Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Psychedelic Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Psychedelic Drugs Market Size (2019-2030)
9.2 Latin America Psychedelic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Psychedelic Drugs Market Size by Country (2019-2024)
9.4 Latin America Psychedelic Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Psychedelic Drugs Market Size (2019-2030)
10.2 Middle East & Africa Psychedelic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Psychedelic Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Psychedelic Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 COMPASS Pathways PLC
11.1.1 COMPASS Pathways PLC Company Detail
11.1.2 COMPASS Pathways PLC Business Overview
11.1.3 COMPASS Pathways PLC Psychedelic Drugs Introduction
11.1.4 COMPASS Pathways PLC Revenue in Psychedelic Drugs Business (2019-2024)
11.1.5 COMPASS Pathways PLC Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Psychedelic Drugs Introduction
11.2.4 Pfizer Revenue in Psychedelic Drugs Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Psychedelic Drugs Introduction
11.3.4 Eli Lilly Revenue in Psychedelic Drugs Business (2019-2024)
11.3.5 Eli Lilly Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Psychedelic Drugs Introduction
11.4.4 GlaxoSmithKline Revenue in Psychedelic Drugs Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 Cybin Inc
11.5.1 Cybin Inc Company Detail
11.5.2 Cybin Inc Business Overview
11.5.3 Cybin Inc Psychedelic Drugs Introduction
11.5.4 Cybin Inc Revenue in Psychedelic Drugs Business (2019-2024)
11.5.5 Cybin Inc Recent Development
11.6 Field Trip Health
11.6.1 Field Trip Health Company Detail
11.6.2 Field Trip Health Business Overview
11.6.3 Field Trip Health Psychedelic Drugs Introduction
11.6.4 Field Trip Health Revenue in Psychedelic Drugs Business (2019-2024)
11.6.5 Field Trip Health Recent Development
11.7 ATAI Life Sciences
11.7.1 ATAI Life Sciences Company Detail
11.7.2 ATAI Life Sciences Business Overview
11.7.3 ATAI Life Sciences Psychedelic Drugs Introduction
11.7.4 ATAI Life Sciences Revenue in Psychedelic Drugs Business (2019-2024)
11.7.5 ATAI Life Sciences Recent Development
11.8 NUMINUS WELLNESS
11.8.1 NUMINUS WELLNESS Company Detail
11.8.2 NUMINUS WELLNESS Business Overview
11.8.3 NUMINUS WELLNESS Psychedelic Drugs Introduction
11.8.4 NUMINUS WELLNESS Revenue in Psychedelic Drugs Business (2019-2024)
11.8.5 NUMINUS WELLNESS Recent Development
11.9 MindMed
11.9.1 MindMed Company Detail
11.9.2 MindMed Business Overview
11.9.3 MindMed Psychedelic Drugs Introduction
11.9.4 MindMed Revenue in Psychedelic Drugs Business (2019-2024)
11.9.5 MindMed Recent Development
11.10 HAVN Life Sciences
11.10.1 HAVN Life Sciences Company Detail
11.10.2 HAVN Life Sciences Business Overview
11.10.3 HAVN Life Sciences Psychedelic Drugs Introduction
11.10.4 HAVN Life Sciences Revenue in Psychedelic Drugs Business (2019-2024)
11.10.5 HAVN Life Sciences Recent Development
11.11 Seelos Therapeutics
11.11.1 Seelos Therapeutics Company Detail
11.11.2 Seelos Therapeutics Business Overview
11.11.3 Seelos Therapeutics Psychedelic Drugs Introduction
11.11.4 Seelos Therapeutics Revenue in Psychedelic Drugs Business (2019-2024)
11.11.5 Seelos Therapeutics Recent Development
11.12 Jannsen
11.12.1 Jannsen Company Detail
11.12.2 Jannsen Business Overview
11.12.3 Jannsen Psychedelic Drugs Introduction
11.12.4 Jannsen Revenue in Psychedelic Drugs Business (2019-2024)
11.12.5 Jannsen Recent Development
11.13 Acadia Pharmaceuticals
11.13.1 Acadia Pharmaceuticals Company Detail
11.13.2 Acadia Pharmaceuticals Business Overview
11.13.3 Acadia Pharmaceuticals Psychedelic Drugs Introduction
11.13.4 Acadia Pharmaceuticals Revenue in Psychedelic Drugs Business (2019-2024)
11.13.5 Acadia Pharmaceuticals Recent Development
11.14 Intellipharmaceutics
11.14.1 Intellipharmaceutics Company Detail
11.14.2 Intellipharmaceutics Business Overview
11.14.3 Intellipharmaceutics Psychedelic Drugs Introduction
11.14.4 Intellipharmaceutics Revenue in Psychedelic Drugs Business (2019-2024)
11.14.5 Intellipharmaceutics Recent Development
11.15 Revive Therapeutics
11.15.1 Revive Therapeutics Company Detail
11.15.2 Revive Therapeutics Business Overview
11.15.3 Revive Therapeutics Psychedelic Drugs Introduction
11.15.4 Revive Therapeutics Revenue in Psychedelic Drugs Business (2019-2024)
11.15.5 Revive Therapeutics Recent Development
11.16 Mydecine Innovations Group
11.16.1 Mydecine Innovations Group Company Detail
11.16.2 Mydecine Innovations Group Business Overview
11.16.3 Mydecine Innovations Group Psychedelic Drugs Introduction
11.16.4 Mydecine Innovations Group Revenue in Psychedelic Drugs Business (2019-2024)
11.16.5 Mydecine Innovations Group Recent Development
11.17 Red Light Holland
11.17.1 Red Light Holland Company Detail
11.17.2 Red Light Holland Business Overview
11.17.3 Red Light Holland Psychedelic Drugs Introduction
11.17.4 Red Light Holland Revenue in Psychedelic Drugs Business (2019-2024)
11.17.5 Red Light Holland Recent Development
11.18 Braxia Scientific
11.18.1 Braxia Scientific Company Detail
11.18.2 Braxia Scientific Business Overview
11.18.3 Braxia Scientific Psychedelic Drugs Introduction
11.18.4 Braxia Scientific Revenue in Psychedelic Drugs Business (2019-2024)
11.18.5 Braxia Scientific Recent Development
11.19 Mind Cure Health
11.19.1 Mind Cure Health Company Detail
11.19.2 Mind Cure Health Business Overview
11.19.3 Mind Cure Health Psychedelic Drugs Introduction
11.19.4 Mind Cure Health Revenue in Psychedelic Drugs Business (2019-2024)
11.19.5 Mind Cure Health Recent Development
11.20 Entheon Biomedical
11.20.1 Entheon Biomedical Company Detail
11.20.2 Entheon Biomedical Business Overview
11.20.3 Entheon Biomedical Psychedelic Drugs Introduction
11.20.4 Entheon Biomedical Revenue in Psychedelic Drugs Business (2019-2024)
11.20.5 Entheon Biomedical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Psychedelic Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Psilocybin
Table 3. Key Players of LSD
Table 4. Key Players of MDMA
Table 5. Key Players of DMT
Table 6. Key Players of Ketamine
Table 7. Key Players of Others
Table 8. Global Psychedelic Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Psychedelic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Psychedelic Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Psychedelic Drugs Market Share by Region (2019-2024)
Table 12. Global Psychedelic Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Psychedelic Drugs Market Share by Region (2025-2030)
Table 14. Psychedelic Drugs Market Trends
Table 15. Psychedelic Drugs Market Drivers
Table 16. Psychedelic Drugs Market Challenges
Table 17. Psychedelic Drugs Market Restraints
Table 18. Global Psychedelic Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Psychedelic Drugs Market Share by Players (2019-2024)
Table 20. Global Top Psychedelic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2023)
Table 21. Ranking of Global Top Psychedelic Drugs Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Psychedelic Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Psychedelic Drugs Product Solution and Service
Table 25. Date of Enter into Psychedelic Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Psychedelic Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Psychedelic Drugs Revenue Market Share by Type (2019-2024)
Table 29. Global Psychedelic Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Psychedelic Drugs Revenue Market Share by Type (2025-2030)
Table 31. Global Psychedelic Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Psychedelic Drugs Revenue Market Share by Application (2019-2024)
Table 33. Global Psychedelic Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Psychedelic Drugs Revenue Market Share by Application (2025-2030)
Table 35. North America Psychedelic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Psychedelic Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Psychedelic Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Psychedelic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Psychedelic Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Psychedelic Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Psychedelic Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Psychedelic Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Psychedelic Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Psychedelic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Psychedelic Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Psychedelic Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Psychedelic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Psychedelic Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Psychedelic Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 50. COMPASS Pathways PLC Company Detail
Table 51. COMPASS Pathways PLC Business Overview
Table 52. COMPASS Pathways PLC Psychedelic Drugs Product
Table 53. COMPASS Pathways PLC Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 54. COMPASS Pathways PLC Recent Development
Table 55. Pfizer Company Detail
Table 56. Pfizer Business Overview
Table 57. Pfizer Psychedelic Drugs Product
Table 58. Pfizer Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 59. Pfizer Recent Development
Table 60. Eli Lilly Company Detail
Table 61. Eli Lilly Business Overview
Table 62. Eli Lilly Psychedelic Drugs Product
Table 63. Eli Lilly Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 64. Eli Lilly Recent Development
Table 65. GlaxoSmithKline Company Detail
Table 66. GlaxoSmithKline Business Overview
Table 67. GlaxoSmithKline Psychedelic Drugs Product
Table 68. GlaxoSmithKline Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 69. GlaxoSmithKline Recent Development
Table 70. Cybin Inc Company Detail
Table 71. Cybin Inc Business Overview
Table 72. Cybin Inc Psychedelic Drugs Product
Table 73. Cybin Inc Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 74. Cybin Inc Recent Development
Table 75. Field Trip Health Company Detail
Table 76. Field Trip Health Business Overview
Table 77. Field Trip Health Psychedelic Drugs Product
Table 78. Field Trip Health Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 79. Field Trip Health Recent Development
Table 80. ATAI Life Sciences Company Detail
Table 81. ATAI Life Sciences Business Overview
Table 82. ATAI Life Sciences Psychedelic Drugs Product
Table 83. ATAI Life Sciences Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 84. ATAI Life Sciences Recent Development
Table 85. NUMINUS WELLNESS Company Detail
Table 86. NUMINUS WELLNESS Business Overview
Table 87. NUMINUS WELLNESS Psychedelic Drugs Product
Table 88. NUMINUS WELLNESS Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 89. NUMINUS WELLNESS Recent Development
Table 90. MindMed Company Detail
Table 91. MindMed Business Overview
Table 92. MindMed Psychedelic Drugs Product
Table 93. MindMed Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 94. MindMed Recent Development
Table 95. HAVN Life Sciences Company Detail
Table 96. HAVN Life Sciences Business Overview
Table 97. HAVN Life Sciences Psychedelic Drugs Product
Table 98. HAVN Life Sciences Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 99. HAVN Life Sciences Recent Development
Table 100. Seelos Therapeutics Company Detail
Table 101. Seelos Therapeutics Business Overview
Table 102. Seelos Therapeutics Psychedelic Drugs Product
Table 103. Seelos Therapeutics Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 104. Seelos Therapeutics Recent Development
Table 105. Jannsen Company Detail
Table 106. Jannsen Business Overview
Table 107. Jannsen Psychedelic Drugs Product
Table 108. Jannsen Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 109. Jannsen Recent Development
Table 110. Acadia Pharmaceuticals Company Detail
Table 111. Acadia Pharmaceuticals Business Overview
Table 112. Acadia Pharmaceuticals Psychedelic Drugs Product
Table 113. Acadia Pharmaceuticals Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 114. Acadia Pharmaceuticals Recent Development
Table 115. Intellipharmaceutics Company Detail
Table 116. Intellipharmaceutics Business Overview
Table 117. Intellipharmaceutics Psychedelic Drugs Product
Table 118. Intellipharmaceutics Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 119. Intellipharmaceutics Recent Development
Table 120. Revive Therapeutics Company Detail
Table 121. Revive Therapeutics Business Overview
Table 122. Revive Therapeutics Psychedelic Drugs Product
Table 123. Revive Therapeutics Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 124. Revive Therapeutics Recent Development
Table 125. Mydecine Innovations Group Company Detail
Table 126. Mydecine Innovations Group Business Overview
Table 127. Mydecine Innovations Group Psychedelic Drugs Product
Table 128. Mydecine Innovations Group Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 129. Mydecine Innovations Group Recent Development
Table 130. Red Light Holland Company Detail
Table 131. Red Light Holland Business Overview
Table 132. Red Light Holland Psychedelic Drugs Product
Table 133. Red Light Holland Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 134. Red Light Holland Recent Development
Table 135. Braxia Scientific Company Detail
Table 136. Braxia Scientific Business Overview
Table 137. Braxia Scientific Psychedelic Drugs Product
Table 138. Braxia Scientific Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 139. Braxia Scientific Recent Development
Table 140. Mind Cure Health Company Detail
Table 141. Mind Cure Health Business Overview
Table 142. Mind Cure Health Psychedelic Drugs Product
Table 143. Mind Cure Health Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 144. Mind Cure Health Recent Development
Table 145. Entheon Biomedical Company Detail
Table 146. Entheon Biomedical Business Overview
Table 147. Entheon Biomedical Psychedelic Drugs Product
Table 148. Entheon Biomedical Revenue in Psychedelic Drugs Business (2019-2024) & (US$ Million)
Table 149. Entheon Biomedical Recent Development
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Psychedelic Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Psychedelic Drugs Market Share by Type: 2023 VS 2030
Figure 3. Psilocybin Features
Figure 4. LSD Features
Figure 5. MDMA Features
Figure 6. DMT Features
Figure 7. Ketamine Features
Figure 8. Others Features
Figure 9. Global Psychedelic Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Psychedelic Drugs Market Share by Application: 2023 VS 2030
Figure 11. Depressive Disorders Case Studies
Figure 12. Post-Traumatic Stress Disorders Case Studies
Figure 13. Substance Abuse Disorders Case Studies
Figure 14. Obsessive Compulsive Disorders Case Studies
Figure 15. Others Case Studies
Figure 16. Psychedelic Drugs Report Years Considered
Figure 17. Global Psychedelic Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 18. Global Psychedelic Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Psychedelic Drugs Market Share by Region: 2023 VS 2030
Figure 20. Global Psychedelic Drugs Market Share by Players in 2023
Figure 21. Global Top Psychedelic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2023)
Figure 22. The Top 10 and 5 Players Market Share by Psychedelic Drugs Revenue in 2023
Figure 23. North America Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America Psychedelic Drugs Market Share by Country (2019-2030)
Figure 25. United States Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Canada Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Psychedelic Drugs Market Share by Country (2019-2030)
Figure 29. Germany Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Psychedelic Drugs Market Share by Region (2019-2030)
Figure 37. China Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Japan Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. South Korea Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. India Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Australia Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Psychedelic Drugs Market Share by Country (2019-2030)
Figure 45. Mexico Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Brazil Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Psychedelic Drugs Market Share by Country (2019-2030)
Figure 49. Turkey Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Psychedelic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. COMPASS Pathways PLC Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 52. Pfizer Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 53. Eli Lilly Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 54. GlaxoSmithKline Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 55. Cybin Inc Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 56. Field Trip Health Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 57. ATAI Life Sciences Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 58. NUMINUS WELLNESS Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 59. MindMed Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 60. HAVN Life Sciences Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 61. Seelos Therapeutics Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 62. Jannsen Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 63. Acadia Pharmaceuticals Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 64. Intellipharmaceutics Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 65. Revive Therapeutics Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 66. Mydecine Innovations Group Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 67. Red Light Holland Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 68. Braxia Scientific Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 69. Mind Cure Health Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 70. Entheon Biomedical Revenue Growth Rate in Psychedelic Drugs Business (2019-2024)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
